Friday, January 31, 2025 | 05:57 AM ISTEN Hindi

Home / Companies / News / Specialty drugs may push Sun Pharma's US biz beyond $2 bn by 2025

Specialty drugs may push Sun Pharma's US biz beyond $2 bn by 2025

The share of specialty medicines in overall pharmaceutical spending has been consistently increasing over the past decade, from 22 per cent in 2011 to 39 per cent in 2021

Premium

In FY22, global specialty revenue recorded 39 per cent growth to reach $674 million, riding on the back of Ilumya (psoriasis drug) sales, which went up 81 per cent to $315 million

Sohini Das Mumbai

3 min read Last Updated : Aug 18 2022 | 12:51 AM IST

Betting on its specialty drugs portfolio, analysts expect the revenue from Sun Pharmaceutical Industries’ US business to cross $2 billion by 2025. The Mumbai-based firm is currently working on clinical trials of four specialty drugs.

Specialty medicines are used to treat chronic, complex, and rare diseases. These medicines are typically more expensive than traditional medicines. Also, they differ in terms of the complexity of disease management and their distribution. The share of specialty medicines in overall pharmaceutical spending has been consistently increasing over the past decade, from 22 per cent in 2011 to 39 per cent in 2021. By 2026,

Topics : Sun Pharma pharmaceutical firms Pharma sector Drug pharma products Edelweiss US markets Fosun Pharmaceutical Pharmaceutical

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in